Priming of human eosinophils by platelet-activating factor enhances the number of cells able to bind and respond to opsonized particles
- PMID: 1431137
Priming of human eosinophils by platelet-activating factor enhances the number of cells able to bind and respond to opsonized particles
Abstract
Addition of platelet-activating factor (PAF) to human eosinophils leads to the modulation of eosinophil responses. Earlier work from our laboratory has shown that the respiratory burst and homotypic aggregation response in these cells induced by opsonized particles (serum-treated zymosan, STZ), is strongly enhanced after pretreatment (priming) with PAF. In the present study we have investigated the effect of PAF on the binding of fluorescent STZ particles to human eosinophils. Addition of STZ to eosinophils isolated from the peripheral blood of normal donors results in an interaction of the STZ particles with only 30 to 40% of the cells. Treatment of the eosinophils with PAF (1 microM) for 2 min strongly enhanced the rate of particle binding and also doubled the percentage of eosinophils binding STZ. The effect of PAF priming is most likely mediated by a change in CR3, because it is reversed by mAb B2.12 blocking the iC3b binding site of CR3 and unaffected by mAb IV.3 blocking Fc gamma RII. This change is not an increase in cell surface expression of CR3, and it requires an active cellular metabolism to be maintained. The functional consequences of the effect of PAF on STZ binding were investigated in the nitro-blue tetrazolium dye slide test. PAF priming strongly enhanced the percentage of eosinophils producing oxygen radicals after STZ stimulation. Our findings indicate that the priming phenomenon observed in human eosinophils consists, at least in part, of a recruitment of cells able to interact with and to respond to opsonized particles.
Similar articles
-
Cooperation between Fc gamma receptor II and complement receptor type 3 during activation of platelet-activating factor release by cytokine-primed human eosinophils.J Immunol. 1994 Sep 15;153(6):2729-35. J Immunol. 1994. PMID: 8077677
-
Phospholipase D-derived phosphatidic acid is involved in the activation of the CD11b/CD18 integrin in human eosinophils.Biochem J. 1999 May 15;340 ( Pt 1)(Pt 1):95-101. Biochem J. 1999. PMID: 10229663 Free PMC article.
-
Cytokine-induced protein tyrosine phosphorylation is essential for cytokine priming of human eosinophils.J Allergy Clin Immunol. 1998 Jan;101(1 Pt 1):103-9. doi: 10.1016/S0091-6749(98)70200-3. J Allergy Clin Immunol. 1998. PMID: 9449508
-
Priming of the respiratory burst in human eosinophils is accompanied by changes in signal transduction.J Immunol. 1990 Dec 1;145(11):3883-8. J Immunol. 1990. PMID: 2246518
-
Granulocyte-macrophage colony-stimulating factor, interleukin-3 (IL-3), and IL-5 greatly enhance the interaction of human eosinophils with opsonized particles by changing the affinity of complement receptor type 3.Blood. 1994 May 15;83(10):2978-84. Blood. 1994. PMID: 8180394
Cited by
-
Leukocyte adhesion deficiency type 1 (LAD-1)/variant. A novel immunodeficiency syndrome characterized by dysfunctional beta2 integrins.J Clin Invest. 1997 Oct 1;100(7):1725-33. doi: 10.1172/JCI119697. J Clin Invest. 1997. PMID: 9312170 Free PMC article.
-
Eosinophil-Cryptococcus neoformans interactions in vivo and in vitro.Infect Immun. 1997 May;65(5):1899-907. doi: 10.1128/iai.65.5.1899-1907.1997. Infect Immun. 1997. PMID: 9125578 Free PMC article.
-
Bactericidal activity of human eosinophilic granulocytes against Escherichia coli.Infect Immun. 2001 Jun;69(6):3591-6. doi: 10.1128/IAI.69.6.3591-3596.2001. Infect Immun. 2001. PMID: 11349018 Free PMC article.
-
Priming effect of platelet activating factor on leukotriene C4 from stimulated eosinophils of asthmatic patients.Thorax. 1996 Feb;51(2):155-8. doi: 10.1136/thx.51.2.155. Thorax. 1996. PMID: 8711647 Free PMC article.
-
Differential effects of the PAF receptor antagonist UK-74,505 on neutrophil and eosinophil accumulation in guinea-pig skin.Br J Pharmacol. 1994 Oct;113(2):513-21. doi: 10.1111/j.1476-5381.1994.tb17019.x. Br J Pharmacol. 1994. PMID: 7834203 Free PMC article.